Role of hypermethylation on carcinogenesis in the pancreas

Surgery Today

Volumn 34, Issue 12, 2004, Pages 981-986

  Kuroki, Tamotsu ^a   Tajima, Yoshitsugu ^a   Kanematsu, Takashi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Hypermethylation; Pancreatic cancer; Tumor suppressor gene

Indexed keywords

APC PROTEIN; CYCLIN D2; HEPARAN SULFATE DEXTRO GLUCOSAMINYL 3 O SULFOTRANSFERASE 2; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; SULFOTRANSFERASE; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GENE MUTATION; HUMAN; MOLECULAR BIOLOGY; PANCREAS CANCER; PATHOGENESIS; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; SURVIVAL RATE; THEORETICAL STUDY;

CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, SUPPRESSOR; GENETIC MARKERS; HUMANS; MALE; PANCREATIC NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 12144281209     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00595-004-2858-6     Document Type: Review

References (61)

1. Tsuchiya R, Tajima Y, Matsuzaki S, Onizuka S, Kanematsu T. Early pancreatic cancer. Pancreatology 2001;1:597-603.
2. Matsuno S, Egawa S, Arai K. Trends in treatment for pancreatic cancer. J Hepatobiliary Pancreat Surg 2001;8:544-8.
3. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
4. Goggins M, Kern SE, Offerhaus JA, Hruban RH. Progress in cancer genetics: lessons from pancreatic cancer. Ann Oncol 1999;10:4-8.
5. Bos JL. ras oncogenes in human cancers: a review. Cancer Res 1989;49:4682-9.
6. Hahn SA, Kern SE. Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am 1995;75:857-69.
7. Sakorafas GH, Tsiotou AG. Multi-step pancreatic carcinogenesis and its clinical implications. Eur J Surg Oncol 1999;25:562-5.
8. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16, and DPC4/Smad4. Virchows Arch 2001; 439:798-802.
9. Peter AJ, Peter WL. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
10. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21: 5427-40.
11. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumors. J Pathol 2002;196:1-7.
12. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, et al. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res 2003;9:1441-5.
13. Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Alder H, Williams NN, et al. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of Semaphorin 3B in non-small cell lung cancer. Cancer Res 2003;63:3352-5.
14. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, et al. Allele loss and promoter hypermethylation of VHL, RAR-β, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003;63:3724-8.
15. Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE, et al. Aberrant methylation of Preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 2002;160:1573-81.
16. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003; 22:3806-12.
17. Miyamoto K, Asada K, Fukutomi T, Okochi E, Yagi Y, Hasegawa T, et al. Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung, and pancreatic cancers. Oncogene 2003;22:274-80.
18. Matsubayashi H, Sato N, Fukushima N, Yeo CJ, Walter KM, Brune K, et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 2003;9:1446-52.
19. Fukushima N, Sato N, Sahin F, Su GH, Hruban RH, Goggins M. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 2003; 89:338-43.
20. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000;60:1835-9.
21. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60:4366-71.
22. Sherr CJ. Cancer cell cycles. Science 1996;276:1672-7.
23. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
24. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001;7:584-9.
25. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001;61:2847-51.
26. Klump B, Hsieh CJ, Nehls O, Dette S, Holzmann K, Kieblich R, et al. Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. Br J Cancer 2003;88:217-22.
27. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
28. Huebner K. Tumor suppressors on 3p: a neoclassic quartet. Proc Natl Acad Sci USA 2001;98:14763-5.
29. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315-9.
30. Vavvas D, Li X, Avruch J, Zhang XF. Identification of Norel as a potential Ras effector. J Biol Chem 1998;273:5439-42.
31. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
32. Shworak NW, Liu J, Petros LM, Zhang L, Kobayashi M, Copeland NG, et al. Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem 1999;274:5170-84.
33. Perrimon N, Bernfield M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 2000;404:725-8.
34. Sherr CJ. D-type cyclins. Trends Biochem Sci 1995;20:187-90.
35. Yu J, Leung WK, Ebert MPA, Leong RWL, Tse PCH, Chan MWY, et al. Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer. Br J Cancer 2003;88:1560-5.
36. Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 1999;9:349-57.
37. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387:921-4.
38. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signaling. Nature 1997;387:917-21.
39. Greenhalgh CJ, Hilton DJ. Negative regulation of cytokine signaling. J Leukocyte Biol 2001;70:348-56.
40. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK/ STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28:29-35.
41. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003;101:2784-8.
42. Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H, Shirai T. Genetic progression and divergence in pancreatic carcinoma. Am J Pathol 2000;156:2123-33.
43. Kaiser A, Herbst H, Fisher G, Koenigsmann M, Berdel WE, Riecken EO, et al. Retinoic acid receptor beta regulates growth and differentiation in human pancreatic carcinoma cells. Gastroenterology 1997;113:920-9.
44. Yang Q, Mori I, Shan L, Nakamura M, Nakamura Y, Utsunomiya H, et al. Biallelic inactivation of retinoic acid receptor β2 gene by epigenetic change in breast cancer. Am J Pathol 2001;158:299-303.
45. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, et al. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-7.
46. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992; 1:229-33.
47. Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Ando H, et al. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res 1992;52:6696-8.
48. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-43.
49. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
50. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95.
51. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
52. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003;63:3735-42.
53. Kuroki T, Tomioka T, Tajima Y, Inoue K, Ikematsu Y, Ichinose K, et al. Detection of the pancreas-specific gene in the peripheral blood of patients with pancreatic carcinoma. Br J Cancer 1999;81:350-3.
54. Miyazono F, Takao S, Natsugoe S, Uchikura K, Kijima F, Aridome K, et al. Molecular detection of circulating cancer cells during surgery in patients with biliary-pancreatic cancer. Am J Surg 1999;177:475-9.
55. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11.
56. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001;61:900-2.
57. Schwartsmann G, Fernandes MS, Schaan MD, Moschen M, Gerhardt LM, Di Leone L, et al. Decitabine (5-aza-2́-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 1997:11(suppl 1):S28-31.
58. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2́-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11(suppl 1):S19-23.
59. Aparicio A, Eads CA, Leong LA, Laird PW, Newman EM, Synold TW, et al. Phase I trial of continuous infusion 5-aza-2́-deoxycytidine. Cancer Chemother Pharmacol 2003;51:231-9.
60. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-92.
61. Gerdes B, Ramaswamy A, Ziegler A, Lang SA, Kersting M, Baumann R, et al. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, and RB. Ann Surg 2002;235:51-9.